I. To validate the prognostic association of fthe m7-FLIPI model, demonstrating that the population of follicular lymphoma patients who respond poorly to chemoimmunotherapy are enriched for having a high-risk m7-FLIPI score (integrated biomarker), and that the score is associated with progression-free survival (integrated biomarker). (Primary translational medicine) II. To estimate the 30 month sustained complete response rate (CR30) defined by centrally read PET/CT with each of the regimens in this early relapsing or refractory follicular lymphoma population.